Business Context and Reporting Period
This Form 8-K was filed by Atossa Therapeutics, Inc. on February 21, 2025. The report addresses a regulatory notice received from The Nasdaq Stock Market LLC regarding the company's compliance with listing standards.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on stock listing compliance rather than financial performance metrics.
Material Changes
The primary material event is the receipt of a Nasdaq non-compliance notice. The company's common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).
Outlook, Risks, and Management Commentary
- Compliance Deadline: The company has until August 20, 2025, to regain compliance.
- Remediation Requirement: To comply, the closing bid price must be at least $1.00 per share for a minimum of 10 consecutive business days.
- Contingency: If compliance is not achieved by the initial deadline, the company may be eligible for an additional 180 calendar day compliance period.
- Immediate Impact: The notice has no immediate effect on the listing or trading of the company's common stock on Nasdaq.
- Management Action: The company intends to actively monitor the bid price and is committed to considering available options to regain compliance.
Investor Verification Checklist
- Verify the current trading price of ATOS to assess proximity to the $1.00 threshold.
- Monitor future 8-K filings for updates on compliance status or potential reverse stock splits.
- Review the company's cash position in recent 10-Q or 10-K filings to evaluate financial stability during the compliance period.
- Check for any announcements regarding capital raising activities that could impact share price.